EUVIMEDEUVIMED entdecken
Crossref

Clinical Correlations of α2,6-Sialyltransferase Expression in Colorectal Cancer Patients

M Lise, C Belluco, S P Perera, R Patel, P Thomas, A Ganguly

Hybridoma · 2000

DOI: 10.1089/027245700429828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hybridoma, 2000. Verfasst von M Lise und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Padova, Italy. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have previously demonstrated a link between alpha2,6-Sialyltransferase (alpha2,6-ST; E.C. 2.4.99.1) expression and differentiation of colon tumors. So far, information is not available relative to the expression of alpha2,6-ST in tumors and the survival of patients with colorectal cancer. We have examined the expression of alpha2,6-ST in a variety of colorectal adenocarcinomas (n = 46) at different stages of differentiation (G1 to G3) by immunoperoxidase assay using monoclonal antibody (MAb) 6B9. Clinical outcome of the patients in a 5-year follow-up study has been correlated with the expression of alpha2,6-ST in tumors surgically removed from the same patients. No significant difference in the alpha2,6-ST expression was noted when age, sex, and tumor locations (colon, rectum) were included as parameters. However, 52% of the moderate (G2) and well-differentiated (G1) adenocarcinomas showed stronger alpha2,6-ST expression compared with poorly differentiated (G3) adenocarcinomas. Notably, absence to moderate levels of tumor alpha2,6-ST expression was correlated with 100% survival in patients with stage I and II tumors compared with 64% survival in patients with strong tumor alpha2,6-ST expression (p < 0.01). These studies suggest a negative correlation between the expression of alpha2,6-ST in tumors and a good clinical outcome in colorectal cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAdultAgedAged, 80 and overAntibodies, MonoclonalColorectal NeoplasmsFemaleHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm StagingPrognosisSialyltransferasesSurvival RateTissue Fixationbeta-D-Galactoside alpha 2-6-Sialyltransferase

Substanzen

Antibodies, MonoclonalSialyltransferasesbeta-D-Galactoside alpha 2-6-Sialyltransferase

Autor:innen und Institutionen

  • Department of Surgery, University of Padova, Italy.

Förderung

  • NCI NIH HHS

Zitieren

APA

Lise, M., Belluco, C., Perera, S. P., Patel, R., Thomas, P., & Ganguly, A. (2000). Clinical Correlations of α2,6-Sialyltransferase Expression in Colorectal Cancer Patients. Hybridoma. https://doi.org/10.1089/027245700429828

Vancouver

Lise M, Belluco C, Perera SP, Patel R, Thomas P, Ganguly A. Clinical Correlations of α2,6-Sialyltransferase Expression in Colorectal Cancer Patients. Hybridoma. 2000. doi:10.1089/027245700429828

BibTeX
@article{Lise2000,
  author = {Lise, M and Belluco, C and Perera, S P and Patel, R and Thomas, P and Ganguly, A},
  title = {Clinical Correlations of α2,6-Sialyltransferase Expression in Colorectal Cancer Patients},
  journal = {Hybridoma},
  year = {2000},
  doi = {10.1089/027245700429828}
}
Kostenlos starten →